Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Oxybutynin hydrochloride may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for What Oxybutynin Hydrochloride Oral Solution is Oxybutynin Hydrochloride Oral Solution contains a medicine called oxybutynin hydrochloride. This belongs to two groups of medicines called 'anticholinergics' and 'antispasmodics'. How Oxybutynin Hydrochloride Oral Solution works It works by relaxing the muscles of the bladder and stops sudden muscle contractions (spasms). This helps control the release of water (urine). What Oxybutynin Hydrochloride Oral Solution is used for Oxybutynin Hydrochloride Oral Solution can be used in adults and children 5 years or older to treat: Loss of control in passing water (urinary incontinence) Increased need or urgency to pass water (urine) Night time bedwetting, when other treatments have not worked
e Oxybutynin Hydrochloride Oral Solution Do not take Oxybutynin Hydrochloride Oral Solution: If you are allergic to oxybutynin hydrochloride or any of the other ingredients in this medicine (listed in section 6). Signs of an allergic reaction include: a rash, swallowing or breathing problems, swelling of your lips, face, throat or tongue If you have a rare muscle illness called 'Myasthenia gravis' If you have glaucoma (increased pressure in the eye, sometimes sudden and painful with blurred vision or loss of vision) If your gut (stomach or intestine) is blocked, perforated or not working properly If you have a severe form of a condition known as 'ulcerative colitis' If you have sudden widening of the colon, which causes abdominal pain, fever or shock known as 'toxic megacolon' If you have a blockage that makes it difficult for you to pass water (urine) Do not take this medicine if any of the above apply to you. If you are not sure, talk to your doctor or pharmacist before taking Oxybutynin Hydrochloride Oral Solution. Warnings and precautions Talk to your doctor or pharmacist before taking Oxybutynin Hydrochloride Oral Solution Especially be careful if you have kidney or liver problems you have an illness affecting the nerves called 'autonomic neuropathy' (e.g. Parkinson's disease) you have an overactive thyroid gland (Hyperthyroidism) you have heart disease or high blood pressure you have an irregular heartbeat (palpitations, arrythmias) and/or increased or rapid heartbeat you have an enlarged prostate gland (prostatic hypertrophy) you have gastro-intestinal disorders or a disease called ulcerative colitis. you have indigestion or heart burn caused by a 'hiatus hernia' (where part of your stomach pushes through the diaphragm) gastro-oesophageal reflux and/or you are using medicinal products that can cause or worsen oesophagitis. you have a raised body temperature or fever you will be taking this medicine in a hot climate Oxybutynin may reduce the amount of saliva resulting in tooth decay or fungal infection of the mouth. Oxybutynin can cause glaucoma (increased pressure in the eye) please contact your doctor immediately if you suffer any blurred vision, loss of vision or have any pain in the eye. Oxybutynin can cause hallucinations, agitation, confusion or somnolence so that your doctor might consider to monitor you. If you are not sure if any of the above apply to you, talk to your doctor or pharmacist before taking Oxybutynin Hydrochloride Oral Solution. Elderly People 65 years of age or older should take Oxybutynin Hydrochloride Oral Solution with caution, because of the risk of cognitive impairment and being at a greater risk of occurrence of adverse reactions. Children and adolescents Children under 5 years of age Do not give this medicine to children under the age of 5 years. Children 5 years of age or older Oxybutynin Hydrochloride Oral Solution should be taken with caution as they may be more sensitive to the effects of the product and at a greater risk of occurrence of adverse reactions. Other medicines and Oxybutynin Hydrochloride Oral Solution Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This is because oxybutynin can affect the way some other medicines work. Also, some medicines can affect the way oxybutynin works. In particular, tell your doctor if you are taking any of the following: Other anticholinergic or antimuscarinic medicines – such as some medicines for irritable bowel syndrome, asthma or incontinence, motion sickness or movement disorders associated with Parkinson's disease Medicines used to make you feel sleepy (sedatives) Medicines used to treat nausea and vomiting (prochlorperazine or chlorpromazine) Medicines used to treat certain mental illnesses – such as clozapine, phenothiazines, haloperidol or benperidol (butyrophenones) Medicines used to treat dementia e. g. donepezil, rivastigmine, galantamine or tacrine (cholinesterase inhibitors) Medicines for depression such as amitriptyline, imipramine or dosulepin ('tricyclic antidepressants") Amantadine, – used in Parkinson's disease or to treat and prevent some virus infections L-dopa or biperidin used to treat Parkinson's disease Digoxin or quinidine used to treat heart problems Atropine which is used to treat certain types of poisonings, a slow heart rate, some eye conditions or is given during surgery. Medicines for stomach and bowel related problems – such as Domperidone, Metoclopromide, Bethanechol Medicines to treat allergic symptoms (antihistamines) CYP3A inhibitor e. g. ketoconazole, itraconazole or fluconazole used to treat fungal infections or erythromycin or other macrolide antibiotics used to treat bacterial infections Oxybutynin with alcohol If you drink alcohol while using Oxybutynin, you may become very drowsy. Pregnancy and breast-feeding Talk to your doctor before taking this medicine if: You are pregnant, think you might be pregnant or are planning to have a baby. You are breast-feeding or planning to breast-feed.This is because small amounts may pass into mothers' milk. Breast feeding while using oxybutynin is therefore not recommended. Ask your doctor or pharmacist for advice before taking any medicine if you are pregnant or breastfeeding. Driving and using machines You may feel drowsy or have blurred vision while you are taking this medicine. If this happens, do not drive or use any tools or machines. Oxybutynin Hydrochloride Oral Solution contains: This medicine contains less than 1 mmol sodium (23 mg) per 5ml that is to say essentially 'sodium-free' This medicine contains 5.90mg of sodium benzoate (E211) in each 5ml. This medicine contains 1.30g sorbitol in each 5ml. Sorbitol is a source of fructose. If your doctor has told you that you (or your child) have an intolerance to some sugars or if you have been diagnosed with hereditary fructose intolerance (HFI), a rare genetic disorder in which a person cannot break down fructose, talk to your doctor before you (or your child) take or receive this medicine. Sorbitol may cause gastrointestinal discomfort and mild laxative effect
Oxybutynin Hydrochloride Oral Solution Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. Taking this medicine Take this medicine by mouth Take Oxybutynin oral solution with a glass of water Always use the syringe supplied with the pack Do not give this medicine to children under 5 years old If you feel the effect of your medicine is too weak or too strong, do not change the dose yourself, but ask your doctor Measuring your dose 2 Instructions for use of the syringe 3 4 1. To open the bottle, press the cap down and turn it anti-clockwise 1 (figure 1). 2 Put the syringe adaptor into the bottle neck (figure 2). 3. Take the syringe and put it into the adaptor opening (figure 3). 4. Turn the bottle upside down (figure 4). 5. Fill the syringe with a small amount of solution by pulling the plunger down (figure 4A).Then push the 4 A 4 C 4 B plunger upward in order to remove any possible bubbles (figure 4B). Finally, pull the plunger down to the graduation mark corresponding to the quantity in millilitres (ml) prescribed by your doctor.The top flat 0.5 edge of the piston should be in line with the graduation mark you are measuring to (Figure 4C). 1,0 ml 6. Turn the bottle the right way up (Figure 5A). 7. Remove the syringe from the adaptor (Figure 5B). 1,5 ml 8. Put the end of the syringe into your mouth and push the plunger slowly back in to take the medicine (Figure 6). 9. Wash the syringe with water and let it dry before you use 6 5 A 5 B it again. 10.Close the bottle with the plastic screw cap – leave the syringe adaptor in the bottle. How much to take Your doctor will decide the dose appropriate for you. Adults The usual dose is 5mg (5ml) two or three times each day Your doctor may decide to increase to the maximum dose of 5mg (5ml) four times each day Elderly The usual dose is 2.5mg (2.5ml) twice each day Your doctor may decide to increase this to 5mg (5ml) twice each day Children (over 5 years) The usual dose is 2.5mg (2.5ml) twice each day Your doctor may decide to increase this to 5mg (5ml) two or three times each day If you are giving it to a child to prevent bedwetting, give the last dose just before bedtime 2,0 ml 2.0
1,5 ml
1,0 ml 0.5 ml
0.5 ml
1,0 ml
1,5 ml
2,0 ml 2.0
0.5 ml
0.5 ml
0.5 ml
1,0 ml
1,0 ml
1,0 ml
1,5 ml
1,5 ml
1,5 ml
2,0 ml 2.0
2,0 ml 2.0
2,0 ml 2.0
1,0 ml
1,5 ml
2,0 ml 2.0
1,5 ml
1,5 ml
1,0 ml
1,0 ml 0.5 ml
ml 2,0 2.0
1,5
1,0
0.5 ml
ml
ml
0.5 ml
G4BD1RBJ1 V12
Continued overleaf
If you take more Oxybutynin Hydrochloride Oral Solution than you should If you take more oxybutynin than you should, tell a doctor or go to a hospital casualty department straight away.Take the medicine pack with you.This is so the doctor knows what you have taken. Taking too much oxybutynin can be very dangerous.You may become very restless or excited, flushed or get dizzy or light-headed.Your heartbeat may become very fast, uneven or forceful or your blood pressure drops.You may get breathing problems or numbness or go into a coma. If you forget to take Oxybutynin Hydrochloride Oral Solution If you forget a dose, take it as soon as you remember it. However, if it is nearly time for the next dose, skip the missed dose. Do not take a double dose to make up for a forgotten dose. If you stop taking Oxybutynin Hydrochloride Oral Solution Keep taking oxybutynin until your doctor tells you to stop. Do not stop taking oxybutynin just because you feel better. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them. Stop taking Oxybutynin Hydrochloride Oral Solution and see a doctor or go to a hospital straight away if: Frequency unknown You have an allergic reaction.The signs may include: a rash, swallowing or breathing problems, swelling of your, lips, face, throat or tongue You may feel reduced sweating, leading to overheating in hot environments Tell your doctor or pharmacist if any of the following side effects get serious or lasts longer than a few days: Very common (affects more than 1 in 10 people) Constipation Nausea Dry mouth Dry skin Headache Somnolence (feeling drowsy or sleepy) Dizziness Blurring of vision Common (affects 1 to 10 people in a 100 people) Dry eyes Diarrhoea Being sick (vomiting) Confusion Flushing especially in children Inability to completely empty the bladder (urinary retention) A forceful heartbeat that may be rapid or irregular Uncommon (affects 1 to 10 people in a 1,000) Stomach pain Loss of appetite (anorexia) Difficulty in swallowing (dysphagia) Frequency not known: frequency cannot be estimated from the available data Increased pressure in the eyes sometimes sudden and painful with blurred vision or loss of vision (glaucoma) Indigestion or heartburn (acid reflux) Urinary tract infection Heat stroke Difficulty passing water (urine) Agitation Anxiety Becoming dependent on oxybutynin if there is a history of drug or substance abuse Feeling excessive suspicious and distrustful of others Mental Health disorders (especially in the elderly) Seeing or hearing things that are not there (hallucinations) Drowsiness Nightmares Fits (convulsions) Depression Increased heartbeat (tachycardia) Irregular heartbeat (arrhythmia) Dilation of pupil (mydriasis) Itchy, lumpy rash (urticaria) Absence of sweating (hypohidrosis) Skin that is more sensitive to the sun (photosensitivity) Disorientation Cognitive disorders Nosebleed Angioedema Muscle weakness, pain or cramps Additional side effects in children Children are at higher risk of the effects. Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse.This includes any possible side effects not listed in this leaflet.You can also report side effects directly via theYellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRAYellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
Oxybutynin Hydrochloride Oral Solution Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date (month, year) which is stated on the label after "EXP". The expiry date refers to the last day of that month. Do not store above 30oC. Store in the original bottle in order to protect from light. After first opening of the bottle: Use within 30 days. Do not use this medicine if you notice anything wrong with the medicine.Talk to your pharmacist. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required.These measures will help to protect the environment.
What Oxybutynin Hydrochloride 5mg/5ml Oral Solution contains The active substance is oxybutynin hydrochloride. Each 5ml of the solution contains 5mg oxybutynin hydrochloride. The other ingredients are citric acid monohydrate (E330), sodium citrate (E331), sodium benzoate (E211), non-crystallising liquid sorbitol (70%) (E420), glycerol (E422), strawberry flavour, and purified water. What Oxybutynin Hydrochloride 5mg/5ml Oral Solution looks like and contents of the pack Oxybutynin Hydrochloride Oral Solution is a clear colourless to slightly straw coloured liquid. It comes in a brown glass bottle holding 150ml of solution with a 5ml purple syringe and bottle adaptor. Marketing Authorisation Holder and Manufacturer Rosemont Pharmaceuticals Ltd, Rosemont House,Yorkdale Industrial Park, Braithwaite Street, Leeds, LS11 9XE, UK. This leaflet was last revised in 09/2024. If you would like this leaflet in different format information, please contact marketing authorisation holder listed above.
G4BD1RBJ1 V12
Oxybutynin Hydrochloride 5 mg/5 ml Oral solution comes as oral solution containing 5mg / 5ml. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Oxybutynin Hydrochloride 5 mg/5 ml Oral solution is oxybutynin hydrochloride.
Medicines with the same active substance, strength and form include: Oxybutynin hydrochloride 5 mg/5 ml oral solution, Oxybutynin hydrochloride 5mg/5ml Oral Solution. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Oxybutynin Hydrochloride 5 mg/5 ml Oral solution, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Oxybutynin hydrochloride is indicated for the symptomatic treatment of urinary incontinence, urgency and frequency in the unstable bladder, whether due to neurogenic bladder disorders (detrusor hyperreflexia) in conditions such as multiple sclerosis and spina bifida, or to idiopathic detrusor instability (motor urge incontinence).
Paediatric population
Oxybutynin hydrochloride is indicated in children of 5 years of age or older for:
- Urinary incontinence, urgency and frequency in unstable bladder conditions due to idiopathic overactive bladder or neurogenic bladder disorders (detrusor overactivity).
- Nocturnal enuresis associated with detrusor overactivity, in conjunction with non- drug therapy, when other treatment has failed.
Dosage
Adults: The usual dose is 5mg two or three times a day. This may be increased to a maximum of 5mg four times a day (maximum dose 20 mg Oxybutynin hydrochloride per day) to obtain a clinical response provided that the side effects are tolerated.
Elderly : The elimination half-life is increased in the elderly. Therefore, a dose of 2.5mg twice a day, particularly if the patient is frail, is likely to be adequate. This dose may be increased to 5mg two times a day to obtain a clinical response provided the side effects are well tolerated.
Children (under 5 years of age): Not recommended
Children (5 years of age or older): Neurogenic bladder instability: the usual dose is 2.5mg twice a day. This dose may be increased to 5mg two or three times a day to obtain a clinical response provided the side effects are well tolerated.
Nocturnal enuresis: the usual dose is 2.5mg twice a day. This dose may increased to 5mg two or three times a day to obtain a clinical response provided the side effects are tolerated. The last dose should be given before bedtime
Method of administration
For oral administration.
Take Oxybutynin oral solution with a glass of water.
An oral dosing device is provided with the pack. For instructions on how to use the device, refer to section 6.6.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Myasthenia gravis.
Narrow-angle glaucoma or shallow anterior chamber.
Gastrointestinal obstructive disorders including paralytic ileus, intestinal atony.
Patients with toxic megacolon.
Patients with severe ulcerative colitis.
Patients with bladder outflow obstruction where urinary retention may be precipitated.
• Oxybutynin should be used with caution in patients with Parkinson's disease who are at greater risk of occurrence of adverse reactions to the product and in patients with autonomic neuropathy (such as those with Parkinson's disease), severe gastro- intestinal motility disorders, hepatic or renal impairment.
• Anticholinergic medicinal products may decrease gastrointestinal motility and should be used with caution in patients with gastrointestinal obstructive disorders, intestinal atony and ulcerative colitis.
• Oxybutynin may aggravate cognitive disorders, symptoms of prostatic hypertrophy and tachycardia (thus be cautious in case of hyperthyroidism, congestive heart failure, cardiac arrhythmia, coronary heart disease, hypertension).
• Anticholinergic CNS effects (e.g. hallucinations, agitation, confusion, somnolence) have been reported; monitoring recommended, particularly in first few months after initiating therapy or increasing the dose. If anticholinergic CNS effects develop, termination of treatment or dose reduction may be considered.
• Since oxybutynin can cause narrow-angle glaucoma, patients should be advised to contact a physician immediately if they are aware of a sudden loss of visual acuity or ocular pain.
• Oxybutynin may reduce salivary secretions which could result in dental caries, parodontosis or oral candidiasis.
• Anticholinergic medicinal products should be used with caution in patients who have hiatus hernia/gastro-oesophageal reflux and/or who are concurrently taking medicinal products (such as bisphosphonates) that can cause or exacerbate oesophagitis.
• When oxybutynin is used in high environmental temperatures, this can cause heat prostration due to decreased sweating.
Elderly
Anticholinergic medicinal products should be used with caution in elderly patients due to the risk of cognitive impairment. They also have a higher risk of occurrence of adverse reactions to the product.
Paediatric population
The use of oxybutynin in children under 5 years of age is not recommended; it has not been established whether oxybutynin can be safely used in this age group.
There is limited evidence supporting the use of oxybutynin in children with monosymptomatic nocturnal enuresis (not related to detrusor overactivity).
In children over 5 years of age, oxybutynin hydrochloride should be used with caution as they may be more sensitive to the effects of the product, particularly the CNS and psychiatric adverse reactions.
Excipient Warnings
• This medicine contains less than 1 mmol sodium (23mg) per 5ml, that is to say essentially 'sodium-free'.
• This medicine contains 5.90mg sodium benzoate (E211) in each 5ml.
• This medicine contains 1.30g sorbitol solution (E420) in each 5ml. The additive effect of concomitantly administered products containing sorbitol (or fructose) and dietary intake of sorbitol (or fructose) should be taken into account. The content of sorbitol in medicinal products for oral use may affect the bioavailability of other medicinal products for oral use administered concomitantly. Patients with hereditary fructose intolerance (HFI) should not take/be given this medicinal product. Sorbitol may cause gastrointestinal discomfort and mild laxative effect.
Care should be taken if other anticholinergic agents are administered together with oxybutynin, as potentiation of anticholinergic effects could occur.
The anticholinergic activity of oxybutynin is increased by concurrent use of other anticholinergics or medicinal products with anticholinergic activity, such as amantadine and other anticholinergic antiparkinsonian medicinal products (e.g. biperiden, levodopa), antihistamines, antipsychotics (e.g. phenothiazines, butyrophenones, clozapine), quinidine, digitalis, tricyclic antidepressants, atropine and related compounds like atropinic antispasmodics and dipyridamole.
By reducing gastric motility, oxybutynin may affect the absorption of other drugs. Oxybutynin is metabolised by cytochrome P 450 isoenzyme CYP 3A4. Concomitant administration with a CYP3A4 inhibitor can inhibit oxybutynin metabolism and increase oxybutynin exposure.
Oxybutynin, as an anticholinergic agent, may antagonize the effect of prokinetic therapies.
Concomitant use with cholinesterase inhibitors may result in reduced cholinesterase inhibitor efficacy.
Patients should be informed that alcohol may enhance the drowsiness caused by anticholinergic agents such as oxybutynin (see section 4.7).
Pregnancy
There are no adequate data from the use of oxybutynin in pregnant women. Animal studies are insufficient with respect to effects on pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3). The potential risk for humans is unknown. Oxybutynin should not be used during pregnancy unless clearly necessary.
Breast-feeding
When oxybutynin is used during lactation, a small amount is excreted in mother's milk. Use of oxybutynin during breast feeding is therefore not recommended.
Oxybutynin may cause drowsiness or blurred vision. Patients should be cautioned regarding activities requiring mental alertness such as driving, operating machinery or performing hazardous work while taking this drug.
Like all medicines, oxybutynin can cause undesirable effects, although not everybody gets them. The frequency of possible undesirable effects listed below are currently defined as:
Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data).
Table 1: Adverse effects and their frequencies:
Body systems
Very common
(≥1/10)
Common
(≥1/100 to <1/10)
Uncommon
(≥ 1 /1000 to <1 / 100)
Not known
Infections and infestations
-
-
-
urinary tract infection
Gastrointestinal disorders
constipation, nausea, dry mouth
diarrhoea, vomiting
abdominal discomfort, anorexia, decreased appetite, dysphagia
gastroesophageal reflux disease, pseudo- obstruction in patients at risk (elderly or patients with constipation and treated with other drugs that decrease intestinal motility)
Psychiatric disorders
-
confusional state
-
agitation, anxiety, hallucinations, nightmares, paranoia, cognitive disorders in elderly, symptoms of depression, dependence to oxybutynin (in patients with history of drug or substance abuse)
Nervous system disorders
dizziness, headache, somnolence
-
-
cognitive disorders, convulsions, drowsiness, disorientation
Cardiac disorders
-
Palpitation
-
tachycardia, arrhythmia
Injury, poisoning and procedural complications
-
-
-
heat stroke
Eye disorders
vision blurred
dry eyes
-
Angle closure glaucoma, mydriasis, ocular hypertension
Renal and urinary disorders
-
urinary retention
-
difficulty in micturition
Vascular disorders
-
flushing which may be more marked in children
-
-
Skin and subcutaneous tissue disorders
dry skin
-
-
angioedema, rash, urticaria, hypohidrosis, photosensitivity
Immune system disorders
-
-
-
Hypersensitivity
Respiratory, thoracic, and mediastinal disorders
-
-
-
Epistaxis
Musculoskeletal and connective tissue disorders
-
-
-
Muscle disorders manifested as muscle weakness, myalgia and/ or muscle spasms
Reporting of suspected adverse reactions:
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme. Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Symptoms of intoxication
The symptoms of overdosage with oxybutynin progress from an intensification of the usual side effects of CNS disturbances (from restlessness and excitement to psychotic behaviour), circulatory changes (flushing, fall in blood pressure, circulatory failure etc), respiratory failure, paralysis and coma.
Measures to be taken are:
1) immediate gastric lavage
2) physostigmine by slow intravenous injection
Adults: 0.5 to 2.0mg of physostigmine by slow intravenous administration. Repeat after 5 minutes, if necessary up to a maximum total dose of 5mg.
Paediatric population: 30 micrograms/kg of physostigmine by slow intravenous administration. Repeat after 5 minutes, if necessary up to a maximum total dose of 2mg.
Fever should be treated symptomatically with tepid sponging or ice packs.
In pronounced restlessness or excitation, diazepam 10mg may be given by intravenous injection, tachycardia may be treated by intravenous injection of propranolol and urinary retention can be managed by bladder catheterisation.
In the event of progression of the curare- like effect to the paralysis of the respiratory muscles, mechanical ventilation will be required.
Ask anything about Oxybutynin Hydrochloride 5 mg/5 ml Oral solution. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.